Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluorometholone
Drug ID BADD_D00929
Description A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
Indications and Usage For the ophthalmic treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
Marketing Status approved; investigational
ATC Code C05AA06; D07AB06; D07XB04; D10AA01; S01BA07; S01CB05
DrugBank ID DB00324
KEGG ID D01367
MeSH ID D005469
PubChem ID 9878
TTD Drug ID D0P0HT
NDC Product Code 22552-0050; 60758-880; 82298-119; 46439-8770; 82298-120; 11980-211; 11980-228
UNII SV0CSG527L
Synonyms Fluorometholone | FML Liquifilm | PMS-Fluorometholone | PMS Fluorometholone | Cortisdin | Efflumidex | FML Forte | Flucon | Isopto Flucon | Flucon, Isopto | Fluor-Op | Fluor Op | Fluoro-Ophtal | Fluoro Ophtal | Fluoropos | FML
Chemical Information
Molecular Formula C22H29FO4
CAS Registry Number 426-13-1
SMILES CC1CC2C3CCC(C3(CC(C2(C4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abortion spontaneous18.01.04.0010.000375%Not Available
Accommodation disorder06.02.04.001--Not Available
Agranulocytosis01.02.03.001--Not Available
Aplastic anaemia01.03.03.002--Not Available
Cataract06.06.01.001--
Cataract subcapsular06.06.01.002--Not Available
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.0020.000375%Not Available
Conjunctivitis11.01.06.012; 06.04.01.002--
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Drug ineffective08.06.01.0060.001274%Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Endophthalmitis11.01.06.003; 06.04.05.009--
Erythema23.03.06.0010.000375%Not Available
Erythema of eyelid23.03.06.006; 06.04.04.003--Not Available
Eye discharge06.04.05.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye infection11.01.06.001; 06.04.05.007--
Eye infection bacterial11.02.01.015; 06.04.05.013--Not Available
Eye infection fungal11.03.05.017; 06.04.05.020--Not Available
Eye infection viral11.05.04.022; 06.04.05.018--Not Available
Eye irritation06.04.05.0030.002736%Not Available
Eye pain06.08.03.0020.000824%
Eye swelling06.08.03.003--Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Eyelid ptosis06.05.01.002; 17.17.02.004--Not Available
Glaucoma06.03.01.002--
Hepatic necrosis09.01.07.002--
Hyperadrenocorticism24.08.02.005; 14.11.01.009; 05.01.01.003--Not Available
Hypersensitivity10.01.03.003--
The 1th Page    1 2    Next   Last    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene